|
|
|
03.06.26 - 23:15
|
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures (The Newswire)
|
|
|
Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures of the Company (each, a “Convertible Debenture”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering.
The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “Maturity Date”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Deben...
|
|
|
|
|
03.06.26 - 21:18
|
ME Therapeutics Announces Private Placement (Business Wire)
|
|
|
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICESVANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share') and one non-transferrable common share purchase warrant (a “Warrant”), with each Warrant being exercisable into one additional Share at an exercise price of $2.00 each for three years from the date of issuance, subject to an acceleration clause whereby, if the volume weighted average price of the Shares is at or above $3.00 for ten consecutive trading days, the Company may accelerat...
|
|
|
|
|
03.06.26 - 13:48
|
Curaleaf Confirms Effective Date of Reverse Stock Split (PR Newswire)
|
|
|
STAMFORD, Conn., June 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today confirms that the previously announced 1-for-3 reverse stock split of its subordinate......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 02:27
|
Hydreight Announces Refiling of Interim Financial Statements (PR Newswire)
|
|
|
VANCOUVER, BC and LAS VEGAS, June 2, 2026 /PRNewswire/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a U.S.-focused digital health infrastructure platform, announces that it has refiled its condensed interim consolidated financial......
|
|
|
|
|
|
|
|
|
02.06.26 - 22:09
|
BriaCell Therapeutics Announces Closing of Offering (GlobeNewswire EN)
|
|
|
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, were approximately $4.7 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq....
|
|